HTG Molecular Diagnostics Inc (NASDAQ:HTGM)’s share price traded up 3.6% during mid-day trading on Wednesday . The stock traded as high as $2.69 and last traded at $2.58, with a volume of 113,901 shares changing hands. The stock had previously closed at $2.49.

Several equities analysts recently issued reports on the company. Canaccord Genuity lowered their price objective on HTG Molecular Diagnostics from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday, April 4th. Zacks Investment Research upgraded HTG Molecular Diagnostics from a “sell” rating to a “hold” rating in a research note on Wednesday, April 20th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $5.00 price objective (down from $10.00) on shares of HTG Molecular Diagnostics in a research note on Monday, March 28th.

The firm’s 50 day moving average is $2.74 and its 200-day moving average is $2.93. The company’s market cap is $17.73 million.

HTG Molecular Diagnostics (NASDAQ:HTGM) last posted its earnings results on Thursday, May 12th. The company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by $0.19. Equities research analysts predict that HTG Molecular Diagnostics Inc will post ($3.91) earnings per share for the current year.

HTG Molecular Diagnostics, Inc is a provider of instruments and reagents for molecular profiling applications. The Company has developed and markets a technology platform for the routine use of complex molecular profiling. The Company’s HTG Edge platform, consisting of instrumentation, including HTG Edge and HTG EdgeSeq systems, consumables and software analytics, is used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.